The Lancet Oncology Commission warns the shortfall, driven by rising cancer rates and workforce gaps, will place significant strain on health systems worldwide, with the largest shortages expected in nursing and… read more.
The path to wiping out cervical cancer looks increasingly clear – at least for high-income countries with strong uptake of the human papillomavirus (HPV) vaccine and cervical screening…. read more.
Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at… read more.
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing… read more.
A Kaiser Permanente study published by NEJM Catalyst Innovations in Care Delivery provides real-world data on a new approach to cervical cancer screening: giving patients the option to skip the… read more.
Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated Cochrane review finds. This is a shift from… read more.
ImmunityBio announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, Anktiva) plus Bacillus Calmette–Guérin (BCG)… read more.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that final data from the Phase 3 AcceleRET-Lung clinical trial of… read more.
At the 2026 ASCO Annual Meeting, Boehringer Ingelheim presented new data from across its oncology clinical development program, including patient-reported outcomes (PROs) for HERNEXEOS® (zongertinib tablets) in HER2… read more.
Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
Prescriptions for the anti-parasite medication ivermectin doubled in the months following an endorsement by a celebrity during a high-profile podcast as an off-label cancer treatment, a UCLA-led study… read more.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Mekinist. The marketing… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
